Home › Funds › BlackRock › iShares Genomics Immunology and Healthcare ETF
Fund family: BlackRock · Filed by iSHARES TRUST (CIK 1100663) · SEC series S000065599
Ticker: IDNA (C000212225)
“With management” counts the items where the fund’s own filing gives management’s recommendation (FOR or AGAINST): 501 with, 5 against, 7 abstentions (not counted as with management); 1 items carried no recommendation. Shareholder proposals: 0 FOR, 4 AGAINST, 0 abstained, by the filing’s own vote-source field.
The same two figures as BlackRock’s manager page (1,606,521 ballot items across 392 funds and accounts), counted the same way for this fund.
| 2025-2026 | This fund | Items | BlackRock | Items |
|---|---|---|---|---|
| Voted FOR the board's own proposals (directors, pay, auditor, capital, transactions, fund matters) | 88.0% | 440 | 93.6% | 1,355,861 |
| Backed environmental and social shareholder proposals at US companies | n/a | 1 | 5.5% | 6,306 |
Each ballot item this fund voted is set against the votes of the other BlackRock funds and accounts on the same item (same meeting, same proposal): “most funds” is a strict majority of at least three of them, FOR against AGAINST, WITHHOLD or ABSTAIN, with split votes and items not voted left out. Funds in one family can follow separate voting policies, for example ESG funds, sub-advised funds and funds using pass-through voting.
Voted differently from most BlackRock funds on 2 items (0.5% of the 431 items where a comparison was possible).
| Company | Meeting | Item | This fund | Most BlackRock funds | Mgmt | Result |
|---|---|---|---|---|---|---|
| BIONTECH SE | 2026-05-15 | Elections to the Supervisory Board: Prof. Dr. Iris Loew-Friedrich | Against | FOR — 6 of 8 BlackRock funds | Against | — |
| BIONTECH SE | 2026-05-15 | Elections to the Supervisory Board: Prof. Dr. Rudolf Staudigl | Against | FOR — 6 of 8 BlackRock funds | Against | — |
Download all 2 differences (CSV)
| Proposal type | Items | Against management |
|---|---|---|
| Director Elections | 239 | 0 |
| Corporate Governance | 69 | 2 |
| Say-on-Pay | 63 | 0 |
| Compensation | 48 | 1 |
| Audit-related | 47 | 0 |
| Capital Structure | 44 | 0 |
| Extraordinary Transactions | 4 | 0 |
| Shareholder Rights and Defenses | 3 | 1 |
| Other Social Issues | 2 | 1 |
Position = shares voted × a recent share price, for US-listed shares of companies with a page on this site; an estimate for ranking only.
| Company | Meeting | Est. position | Items | Against mgmt |
|---|---|---|---|---|
| MODERNA, INC. | May 6, 2026 | $42M | 5 | 0 |
| MODERNA, INC. | November 12, 2025 | $21M | 2 | 0 |
| REVOLUTION MEDICINES, INC. | June 18, 2026 | $12M | 4 | 0 |
| TWIST BIOSCIENCE CORPORATION | February 5, 2026 | $9M | 5 | 0 |
| EXELIXIS, INC. | May 26, 2026 | $8M | 14 | 0 |
| MERCK & CO., INC. | May 26, 2026 | $8M | 18 | 3 |
| REGENERON PHARMACEUTICALS, INC. | June 12, 2026 | $7M | 7 | 0 |
| VERTEX PHARMACEUTICALS INCORPORATED | May 13, 2026 | $6M | 15 | 1 |
| Meeting | Company | Proposal | Fund | Mgmt |
|---|---|---|---|---|
| May 26, 2026 | MERCK & CO., INC. | Shareholder proposal regarding a report on DEI risks in federal contracting. Shareholder proposal | Against | For |
| May 26, 2026 | MERCK & CO., INC. | Shareholder proposal regarding a report on healthcare coverage gaps. Shareholder proposal | Against | For |
| May 13, 2026 | VERTEX PHARMACEUTICALS INCORPORATED | Shareholder Proposal, if properly presented at the meeting, regarding shareholder right to act by written consent. Shareholder proposal | Against | For |
| June 25, 2026 | VALNEVA SE | Authorize Capital Issuances for Use in Employee Stock Purchase Plans | For | Against |
519 ballot items at 52 meetings in 2025-2026. Download all votes (CSV)
Recent votes against management’s recommendation at large companies.
In the 2025-2026 proxy season, iShares Genomics Immunology and Healthcare ETF (IDNA) voted at 52 shareholder meetings of 49 companies, on 519 ballot items in all. Where management made a recommendation, the fund followed it on 97.7% of the items and voted against it 5 times. Its most frequent area of disagreement was corporate governance (2 of its votes against management). It voted on 4 shareholder proposals. It voted FOR the board's own proposals less often than BlackRock's funds as a whole (88.0% against 93.6%). It voted differently from most BlackRock funds on 2 items.
Every figure is derived from the fund’s own Form N-PX filings with the SEC, read item by item: one ballot item is the fund’s vote on one proposal at one meeting, and an item filed twice in the season is counted once. Percentages count items, never shares. A season is published only with at least 250 ballot items at 15 meetings. Built November 18, 2026; the family figures are those of BlackRock’s manager page. The interactive database shows the same votes company by company, with every other fund that voted.